Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40WEG | ISIN: KYG0411D1236 | Ticker-Symbol:
NASDAQ
27.06.25 | 20:31
6,460 US-Dollar
-5,83 % -0,400
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APOLLOMICS INC Chart 1 Jahr
5-Tage-Chart
APOLLOMICS INC 5-Tage-Chart

Aktuelle News zur APOLLOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.Apollomics tags out of TYG oncology pact to cut costs, extend runway into 20261
03.04.Apollomics Inc. - 20-F, Annual and transition report of foreign private issuers1
APOLLOMICS Aktie jetzt für 0€ handeln
03.04.Apollomics GAAP EPS of -$52.802
03.04.Apollomics Inc.: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress97Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew...
► Artikel lesen
01.04.Apollomics and LaunXP agree on NSCLC treatment in Asia2
31.03.Apollomics hands Asia rights to its lead c-MET inhibitor to Taiwan's LaunXP in $60M deal1
31.03.Apollomics, LaunXP enter development, commercial agreement for Vebreltinib1
31.03.Apollomics Inc.: Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib1
31.03.Apollomics Inc. - 6-K, Report of foreign issuer1
20.12.24Apollomics Inc.: Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia252FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology...
► Artikel lesen
10.12.24Apollomics Inc.: Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement113FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
► Artikel lesen
21.11.24Apollomics Inc.: Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split288FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology...
► Artikel lesen
14.08.24Apollomics Inc.: Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress147Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million...
► Artikel lesen
13.08.24Apollomics Inc.: Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial140FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1